In conclusion, geniposide inhibits key inflammatory signaling pathways, such as the TLR4/NF-κB and MAPK pathways; suppresses the release of inflammatory factors, such as TNF-α, IL-1β and IL-6; and decreases the levels of iNOS and COX-2; thus, geniposide can effectively inhibit the infiltration of inflammatory cells in the liver and represents a therapeutic agent for NAFLD. Here, IL1B is linked to metabolic dysfunction-associated steatotic liver disease.